ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

4 links0 made here, not in the record6 judgments2 judges (our rules as one)9 record changes seen
Claude Opus 5.5Our rulesRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07421167A Study to Assess theTolerability of Ianalumab(VAY736) WithInvestigator's ChoiceThrombopoietin ReceptorAgonist (IC TPO-RA) inPatients With PrimaryNovartis PharmaceuticalsPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Oct 9 · ClinicalTrials.gov record · Version of 2026-10-09Oct 14 · ClinicalTrials.gov record · Version of 2026-10-14Oct 15 · ClinicalTrials.gov record · Version of 2026-10-15Oct 22 · ClinicalTrials.gov record · Version of 2026-10-22Nov 3 · ClinicalTrials.gov record · Version of 2026-11-03Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Nov 17 · ClinicalTrials.gov record · Version of 2026-11-17Version of 2026-11-17CONDITIONSPurpura, Thrombocytopenic, …The registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionEvans SyndromeThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termFinest filed termDRUGSIanalumabIntervention entry›Nov 4 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedTestedThrombopoietin Receptor Ago…Entry “thrombopoietin receptor agonis…›Nov 18 · Our role rule · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Ianalumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “ianalumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 29The record itselfClinicalTrials.gov recordVersion of 2026-09-29Record change
Oct 2The record itselfClinicalTrials.gov recordVersion of 2026-10-02Record change
Oct 9The record itselfClinicalTrials.gov recordVersion of 2026-10-09Record change
Oct 14The record itselfClinicalTrials.gov recordVersion of 2026-10-14Record change
Oct 15The record itselfClinicalTrials.gov recordVersion of 2026-10-15Record change
Oct 22The record itselfClinicalTrials.gov recordVersion of 2026-10-22Record change
Nov 3The record itselfClinicalTrials.gov recordVersion of 2026-11-03Record change
Nov 4IanalumabClaude Opus 5.5TestedCurrent
Nov 6The record itselfClinicalTrials.gov recordVersion of 2026-11-06Record change
Nov 14Purpura, Thrombocytopenic, IdiopathicOur condition-kind ruleFinest filed termCurrent
Nov 14Evans SyndromeOur condition-kind ruleFinest filed termCurrent
Nov 17The record itselfClinicalTrials.gov recordVersion of 2026-11-17Record change
Nov 18IanalumabOur role ruleTestedAgrees
Nov 18Thrombopoietin Receptor AgonistOur role ruleTestedCurrent
As of nowPurpura, Thrombocytopenic, IdiopathicOur main-condition rule (R9)Main conditionCurrent